Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

Core Insights - Oculis Holding AG will host an R&D Day on April 15, 2025, to provide updates on its clinical candidates and future development strategies [1][2][3] Company Overview - Oculis is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema (DME), Licaminlimab for dry eye disease (DED), and Privosegtor for acute optic neuritis [16] Clinical Development Updates - The R&D Day will feature updates on the Phase 3 DIAMOND trials for OCS-01 eye drops in DME, the development plan for Licaminlimab in DED, and expanded data from the ACUITY Phase 2 trial for Privosegtor [2][3] - OCS-01 is a high concentration dexamethasone eye drop aimed at providing a non-invasive treatment for DME, addressing limitations of current invasive treatments [4][5] - Licaminlimab is an anti-TNFα eye drop candidate showing positive effects in Phase 2 trials for DED, with a genetic biomarker identified for improved response [9][10] - Privosegtor has shown neuroprotective benefits in acute optic neuritis, with orphan drug designation from both the FDA and EMA [13][14] Market Need and Impact - DME affects approximately 37 million people globally, with projections to rise to 53 million by 2040, highlighting the urgent need for effective treatments [6][8] - DED impacts over 110 million people in G7 countries, with a significant unmet need as 87% of chronic patients remain unsatisfied with current treatments [11][12] - Acute optic neuritis affects up to 8 in 100,000 people and currently lacks specific neuroprotective therapies, indicating a substantial market opportunity for Privosegtor [15]